Candel Therapeutics (CADL) Return on Capital Employed (2021 - 2025)
Candel Therapeutics (CADL) reported Return on Capital Employed of 48.07% for Q4 2025, up 7709.0% on a YoY basis from 0.62% in Q4 2024, and down 5.07% sequentially from 45.75% in Q3 2025.
Candel Therapeutics (CADL) Return on Capital Employed (2021 - 2025) Analysis & Trends
Candel Therapeutics (CADL) has 5 years of Return on Capital Employed data on file, last reported at 48.07% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 7709.0% year-over-year to 48.07%; the trailing twelve-month figure through Dec 2025 stood at 48.07% (up 7709.0% YoY), and the FY2025 full-year result was 45.09%, up 4632.0% from the prior year.
- Return on Capital Employed slipped to 48.07% in Q4 2025, from 45.75% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 29.5% in Q4 2021 to a low of 407.05% in Q3 2024.
- A 5-year average of 92.3% and a median of 46.96% in 2025 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed sank 32495 bps in 2024 and soared 36130 bps in 2025, its largest moves.
- Tracing CADL's Return on Capital Employed over 5 years: stood at 29.5% in 2021, then slumped by 55 bps to 45.85% in 2022, then plunged by 166 bps to 122.08% in 2023, then fell by 3 bps to 125.16% in 2024, then jumped by 62 bps to 48.07% in 2025.
- Business Quant data shows CADL's Return on Capital Employed at 48.07% in Q4 2025, 45.75% in Q3 2025, and 41.99% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Candel Therapeutics | 542.51 Mn | 542.51 Mn | - | -48.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -48.07% |
| Sep 30, 2025 | -45.75% |
| Jun 30, 2025 | -41.99% |
| Mar 31, 2025 | -41.32% |
| Dec 31, 2024 | -125.16% |
| Sep 30, 2024 | -407.05% |
| Jun 30, 2024 | -240.00% |
| Mar 31, 2024 | -161.70% |
| Dec 31, 2023 | -122.08% |
| Sep 30, 2023 | -82.11% |
| Jun 30, 2023 | -66.04% |
| Mar 31, 2023 | -52.61% |
| Dec 31, 2022 | -45.85% |
| Sep 30, 2022 | -41.27% |
| Jun 30, 2022 | -36.60% |
| Mar 31, 2022 | -33.43% |
| Dec 31, 2021 | -29.50% |
| Sep 30, 2021 | -40.90% |